EGFR and ovarian cancer: Recently, completed phase II trials have evaluated linsitinib combination therapies with paclitaxel in patients with recurrent ovarian cancer and with erlotinib in metastatic EGFR-mutant non-small-cell lung cancer (NSCLC) patients [30, 31].